DiaSorin stock (IT0003492391): Shares gain amid FTSE MIB session

DiaSorin S.p.A. shares emerged as one of the strongest performers on the FTSE MIB index during a session marked by broader declines. The stock reached €68.28, up 2.4% for the day, even as the Investing.com Italy 40 fell 1.38% at the close in Milan, Investing.com as of May 13, 2026. This movement highlights resilience in the diagnostics sector amid European market pressures.

As of: 13.05.2026

By the editorial team – specialized in equity coverage.

DiaSorin: core business model

DiaSorin S.p.A. develops, produces, and commercializes reagent kits for in vitro diagnostics worldwide. The company operates through two main segments: immunodiagnostics and molecular diagnostics, serving hospitals, laboratories, and reference centers. Its platforms enable testing for infectious diseases, bone health, and thyroid conditions, with a focus on high automation and reliability.

Listed on Borsa Italiana under ticker DIAS, DiaSorin generates significant revenue from its LIAISON and Molecular platforms. The firm invests in R&D to expand its test menu, targeting transplant monitoring and autoimmune diseases. For US investors, DiaSorin offers exposure to the growing in vitro diagnostics market, which reached $80 billion in 2025 per MarketScreener as of May 2026.

Main revenue and product drivers for DiaSorin

Immunodiagnostics account for the majority of revenue, driven by the LIAISON XL analyzer and assays for vitamin D, CMV, and EBV testing. Molecular diagnostics contribute through the Liaison MDX platform, used for respiratory and gastrointestinal pathogens. In Q1 2026, shares surged 10% to €68.28 following quarterly results, per Simply Wall St as of May 2026.

Geographic revenue splits show Europe at around 60%, with North America growing via partnerships and direct sales. Key drivers include demand for infectious disease testing post-pandemic and expansion into oncology markers. Analyst consensus targets an average price of €69.86, implying 4.74% upside from €66.70 last close, based on 12 analysts rating it Outperform.

Industry trends and competitive position

The global IVD market is projected to grow at 5-7% CAGR through 2030, fueled by aging populations and personalized medicine. DiaSorin competes with Roche Diagnostics, Abbott, and Siemens Healthineers, differentiating via niche expertise in immunoassay automation. Its 2025 revenue for the full year stood at €1.3 billion (published Q4 2025 report), with EBITDA margins above 30%.

For US investors, DiaSorin's products are integral to hospital labs, providing indirect exposure to US healthcare spending, which totals over $4 trillion annually. Recent FTSE MIB outperformance underscores strength amid volatility.

Why DiaSorin matters for US investors

DiaSorin trades as an ADR in the US (DSRLY), offering retail investors access without direct Milan listing. Its diagnostics focus aligns with US trends in precision medicine and outbreak preparedness. The stock's 2.4% gain on May 13, 2026, to €68.28 on Borsa Italiana beat the FTSE MIB's decline, Borsa Italiana as of May 13, 2026.

Conclusion

DiaSorin S.p.A. demonstrated market resilience with gains to €68.28 on May 13, 2026, amid FTSE MIB declines, supported by strong analyst consensus and diagnostics demand. The company's focus on immunodiagnostics positions it well in a growing sector, with relevance for US investors via ADR access and healthcare exposure. Ongoing quarterly performance will shape near-term trading.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.